Úplné zobrazení záznamu

Toto je statický export z katalogu ze dne 19.12.2020. Zobrazit aktuální podobu v katalogu.

Bibliografická citace

.
0 (hodnocen0 x )
(0.2) Půjčeno:1x 
BK
Sixth edition
Philadelphia : Elsevier, [2019]
xiv, 714 stran : barevné ilustrace ; 28 cm

objednat
ISBN 978-0-323-47652-2 (brožováno)
"Wecker, Lynn, editor. Taylor, David A. (David Alan), 1948- editor. Theobald, Robert James, Jr., editor."--Rub titulní strany
Obsahuje bibliografie, bibliografické odkazy a rejstřík
001481627
CONTENTS // SECTION 1 Mechanisms of Drug Action and Therapeutic Principles // 1. Introduction, 2 // Lynn Wecker // 2 pharmacodynamics: Receptors and Concentration-Response Relationships, 4 // James Carlton Garrison. II // 3. Pharmacokinetics, 20 // Paul F. Hollenberg _ // 4. Pharmacogenetics, 39 // Larisa H Cavallari, Scott A. Mosley, and Julie A. Johnson // 5. Drug Discovery, Development, and Regulation, 47 // James Ł Barrett // SECTION 2 Chemical Mediators and Drugs Affecting Autonomic and Neuromuscular Synapses // 6. Introduction to the Autonomic Nervous System, 54 // Lynn Wecker and Robert J. Theobald, Jr. // Cholinergic Drugs // 7. Muscarinic Agonists, Cholinesterase Inhibitors, and Their Clinical Uses, 64 // F.J. Ehlert // 8. Muscarinic Antagonists and Their Clinical Uses, 74 // F.J. Ehlert // 9. Nicotinic Agonists and Their Clinical Uses, 79 Lynn Wecker and Robert J. Theobald, Jr. // 10. Neuromuscular Blocking Drugs and Nicotinic Antagonists, 83 // Lynn Wecker and Robert J. Theobald, Jr. // Adrenergic Drugs // 11. Adrenergic Agonists and Their Clinical Uses, 89 // Javier Cuevas // 12. Adrenergic Antagonists and Their Clinical Uses, 100 // Javier Cuevas // SECTION 3 Drug Treatment for Disorders Affecting the Central Nervous // ___ System // 13. The Central Nervous System, 109 // Lynn Wecker // 14. Drug Therapy for Alzheimer Disease and Other Cognitive // Disnrders/Dementias, 121 // Michael Jaff??, Meredith Wicklund, Erin Foff, and Steven T. DeKosky // 15 Pharmacotherapy
of Basal Ganglia Disorders: Parkinson Disease and Huntington Disease, 126 // Juan R. Sanchez-Ramos and Briony Catlow // 16. Drug Therapy for Psychoses and Bipolar Disorder, 134 // Lynn Wecker, Glenn W. Currier, and Glenn Catalano // 17. Drug Therapy for Depression and Anxiety, 143 // Lynn Wecker, Deborah L Sanchez, and Glenn W. Currier // 18. Drug Therapy for the Management of Attention Deficit-Hyperactivity Disorder, 157 // D. Samba Reddy // 19. Drug Therapy for Insomnia and the Hypersomnias, 162 // Lynn Wecker // 20. Drug Therapy for Managing Obesity and Eating Disorders, 169 // Charles Rudiek // 21. Treatment of Seizure Disorders, 175 // Michael A. Rogawski // 22. Drug Therapy for Spasticity Disorders, 188 // Michael Saulino // 23. Ethanol, Other Alcohols, and Drugs for Alcohol Use Disorder, 193 // Charles A. Whitmore and Christian J. Hopfer // 24. Illicit Psychoactive Compounds and Substance Use Disorder, 202 // Rex M. Philpot and Peter W. Kalivas // SECTION 4 Drug Therapy for Pain Management // 25. Introduction, 215 // Susan L. Ingram // 26. General Anesthetics, 219 // David R. Wetzel and Jeffrey J. Pasternak // 27. Local Anesthetics, 230 Joshua R. Edwards // 28. Opioid Analgesics, 237 Susan L. Ingram and Elena E. Bagley // 29. Nonsteroidal Antiinflammatory Agents and Acetaminophen, 246 // Jennelle Dumeti Richardson and Jill Fehrenbacher // 30. Cannabinoids as Analgesics, 255 // Rex M. Philpot and Lynn Wecker // SECTION 5 Treatment of Inflammatory, Allergic and Immunological
Disorders // 31. Drug Therapy for Migraine Headache, 262 // D. Samba Reddy // 32. Drug Therapy for Gout and Hyperuricemia, 268 // Keith S. Elmslie // 33. Drug Treatment for Allergic Reactions, 273 // Kirk E. Dineley and Latha Malaiyandi // 34. Immunosuppressants for Autoimmune Disorders and Organ Transplantation, 278 // Kymberly Gowdy // 35. Drug Therapy for Rheumatoid Arthritis, 286 // Keith S. Elmslie // XIII // xiv // CONTENTS // SECTION 6 Drug Treatment for Cardiovascular Diseases // 36. Introduction to the Regulation of Cardiovascular Function, 293 // David A. Taylor and Abdel A. Abdel-Rahman // 37. Overview of Hypertension Management and Drugs That Decrease Sympathetic Tone, 299 // David A. Taylor and Abdel A. Abdel-Rahman // 38. Diuretics and Drugs That Affect Volume and Electrolyte Content, 304 // Abdel A. Abdel-Rahman // 39. Drugs Affecting the Renin-Angiotensin-Aldosterone System, 319 // Abdel A. Abdel-Rahman // 40. Calcium Channel Blockers, 325 // Kelly D. Karpa // 41. Vasodilators for Hypertensive Crises, Pulmonary Hypertension, and Erectile Dysfunction, 330 // David A. Tulis and David S, Middlemas // 42. Drug Therapy for Hyperlipidemias and Atherosclerotic Cardiovascular Disease, 337 // Michael T Piascik and Robert W. Hadley // 43. Drug Therapy for Myocardial Ischemia and Angina Pectoris, 347 // J. West Paul, Jr. // 44. Treatment of Heart Failure, 353 // Michael T Piascik and Robert W. Hadley // 45. Antiarrhythmic Drugs, 361 // David A. Taylor and Stephanie W, Watts
// 46. Anticoagulant, Fibrinolytic, and Antiplatelet Agents, 374 // Frank Herrmann, Paul T Kocis, Kelly D. Karpa, and Kent Ł Vrana // 47. Drug Therapy for Hemophilia and the Deficiency Anemias, 384 // David A. Taylor and Pamela Potter // SECTION 7 Endocrine Pharmacology // 48. Introduction to Endocrine Pharmacology, 391 // Shelley Tischkau // 49. Treatment of Hypothalamic and Pituitary Disorders, 395 // Shelley Tischkau // 50. Treatment of Adrenocorticosteroid Disorders, 403 // Gerald B. Call // 51. Female Hormone Regulation, 410 // Julia Ousterhout // 52. Androgens, Antiandrogens, and Their Clinical Uses, 426 // David S. Middlemas // 53. Drug Therapy for the Management of Diabetes, 433 // Julio A. Copello // 54. Drug Therapy for the Management of Thyroid Disorders, 449 // Shelley Tischkau // 55. Calcium Regulating Hormones and Other Agents Affecting Bone, 455 // Jack W. Strandhoy // SECTION 8 Chemotherapy // Infectious Diseases // 56. Principles of Antimicrobial Use, 464 Rukiyah Van Dross-Anderson and Eman Soliman // 57. Drugs Targeting Bacterial Cell Walls and Membranes, 479 // Rukiyah Van Dross-Anderson and Daniel A. Ladin // 58. Drugs Targeting Bacterial Protein Synthesis, 495 // Rukiyah Van Dross-Anderson and Daniel A. Ladin // 59. Drugs Targeting Bacterial DNA, 508 // Rukiyah Van Dross-Anderson and Ahmed E.M. Elhassanny // 60. Antimycobacterial Agents, 517 // Rukiyah Van Dross-Anderson and Ahmed E.M. Elhassanny // 61. Drugs Targeting Resistant Organisms, 526 // Rukiyah
Van Dross-Anderson and Ahmed E.M. Elhassanny // Parasitic Diseases // 62. Antifungal Agents, 532 // Mona M. McConnaughey and J. Scott McConnaughey // 63. Antimalarial and Other Antiprotozoal Agents, 542 // Adonis McQueen // 64. Anthelmintics and Ectoparasiticides, 550 // Mona M. McConnaughey and J. Scott McConnaughey // Viruses // 65. Antiviral Agents, 555 // LaToya M. Griffin and Margaret Nelson // 66. Antiretroviral Drugs for HIV, 565 // Amy Wecker // Cancer // 67. Principles of Antineoplastic Drug Use, 575 // John S. Lazo // 68. Cytotoxic Agents, 582 // Mary-Ann Bjornsti // 69. Targeted Anticancer Agents, 598 // Jill Marie Siegfried // SECTION 9 Special Considerations // 70. Therapeutic Use of Hematopoietic Growth Factors, 610 // Pamela Potter // 71. Gastrointestinal Disorders and Their Treatment, 615 // Walter Prozialeck and Phillip Kopf // 72. Pharmacological Treatment of Asthma and COPD, 626 // Kirk E Dineley and Latha Malaiyandi // 73. The Role of Nutraceuticals and Natural Products, 634 // Pamela Potter // 74. Essentials of Toxicology, 640 // Monica Valentovic and Gary Rankin // 75. Therapeutic Considerations for Pregnant, Pediatric, Geriatric, and Obese Individuals, 645 // Margaret Nelson and LaToya M. Griffin

Zvolte formát: Standardní formát Katalogizační záznam Zkrácený záznam S textovými návěštími S kódy polí MARC